A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-posit

• Status: RECRUITING
• Trial end date: 2035-01-19

Summary

This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.

• Phase: PHASE3

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Daiichi Sankyo
• Treatments: Carboplatin; Cisplatin; Etoposide; Pemetrexed; Vinorelbine